-
-
-
-
-
-
-
Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders
-
-
-
-
-
-
-
Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors
-
-
-
-
-
-
-
Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
-
-
-
-
-
-
-
Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs
-
-
-
-
-
-
-
BMO Capital Downgrades Incyte (INCY) to Underperform
-
-
-
-
-
-
-
BMO Capital Reiterates Market Perform Rating on Incyte (INCY)
-
-
-
-
-
-
-
MorphoSys shares soar on report Novartis is in advanced talks to acquire the company
-
1,162,761 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

